Urokinase Plasminogen Activator System in Benign Prostatic Hyperplasia: A Possible Marker of Progression and Response to Medical Therapy
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Sponsor
- Queen's University
- Enrollment
- 30
- Locations
- 1
Study Overview
Brief Summary
We hypothesize that the absolute or relative serum or urine levels of the urokinase plasminogen activator system, including uPA, uPAR and PAI-1,2 (inhibitors of the uPAR/uPA complex), are associated with inflammation in prostatic tissue.
Detailed Description
Histological inflammation in patients with Benign Prostatic Hyperplasia (BPH) appears to predict clinical progression and ultimate long-term response to various medical therapies, including finasteride. Discovery of a urine or serum marker of prostate inflammation will be an invaluable clinical tool to predict a man's risk of BPH progression and the efficacy of various medical therapies to reduce that risk.
Specific Aim:
We plan to determine if urokinase plasminogen activators (and/or other inflammatory markers) in serum, urine and tissue of patients can predict prostatic inflammation
Background:
Benign Prostatic Hyperplasia (BPH) and Inflammation
Study Design
- Study Type
- Observational
- Observational Model
- Case Only
- Time Perspective
- Prospective
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- Male
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •scheduled for transurethral resection of the prostate
Exclusion Criteria
- •unable to give consent
Investigators
Dr. J. Curtis Nickel
Professor
Queen's University